Monoclonal antibody proteomics: Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step

Eszter Csanky, Petra Olivova, E. Rajnavolgyi, William Hempel, Nadege Tardieu, Elesne Toth Katalin, Anne Jullien, Carole Malderez-Bloes, Mariana Kuras, Manuel X. Duval, L. Nagy, B. Scholtz, William Hancock, Barry Karger, A. Guttman, Laszlo Takacs

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We define mAb proteomics as the global generation of disease specific antibodies that permit mass screening of biomarkers. An integrated, high-throughput, disease-specific mAb-based biomarker discovery platform has been developed. The approach readily provided new biomarker leads with the focus on large-scale discovery and production of mAb-based, disease-specific clinical assay candidates. The outcome of the biomarker discovery process was a highly specific and sensitive assay, applicable for testing of clinical validation paradigms, like response to treatment or correlation with other clinical parameters. In contrast to MS-based or systems biology-based strategies, our process produced prevalidated clinical assays as the outcome of the discovery process. By re-engineering the biomarker discovery paradigm, the encouraging results presented in this paper dearly demonstrate the efficiency of the mAb proteomics approach, and set the grounds for the next steps of studies, namely, the hunt for candidate biomarkers that respond to drug treatment.

Original languageEnglish
Pages (from-to)4401-4406
Number of pages6
JournalElectrophoresis
Volume28
Issue number23
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Pulmonary diseases
Biomarkers
Proteomics
Chronic Obstructive Pulmonary Disease
Monoclonal Antibodies
Assays
Drug therapy
Mass Screening
Systems Biology
Screening
Throughput
Antibodies
Testing
Pharmaceutical Preparations

Keywords

  • Antibody
  • Biomarker discovery
  • Proteomics

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Monoclonal antibody proteomics : Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step. / Csanky, Eszter; Olivova, Petra; Rajnavolgyi, E.; Hempel, William; Tardieu, Nadege; Katalin, Elesne Toth; Jullien, Anne; Malderez-Bloes, Carole; Kuras, Mariana; Duval, Manuel X.; Nagy, L.; Scholtz, B.; Hancock, William; Karger, Barry; Guttman, A.; Takacs, Laszlo.

In: Electrophoresis, Vol. 28, No. 23, 12.2007, p. 4401-4406.

Research output: Contribution to journalArticle

Csanky, E, Olivova, P, Rajnavolgyi, E, Hempel, W, Tardieu, N, Katalin, ET, Jullien, A, Malderez-Bloes, C, Kuras, M, Duval, MX, Nagy, L, Scholtz, B, Hancock, W, Karger, B, Guttman, A & Takacs, L 2007, 'Monoclonal antibody proteomics: Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step', Electrophoresis, vol. 28, no. 23, pp. 4401-4406. https://doi.org/10.1002/elps.200700256
Csanky, Eszter ; Olivova, Petra ; Rajnavolgyi, E. ; Hempel, William ; Tardieu, Nadege ; Katalin, Elesne Toth ; Jullien, Anne ; Malderez-Bloes, Carole ; Kuras, Mariana ; Duval, Manuel X. ; Nagy, L. ; Scholtz, B. ; Hancock, William ; Karger, Barry ; Guttman, A. ; Takacs, Laszlo. / Monoclonal antibody proteomics : Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step. In: Electrophoresis. 2007 ; Vol. 28, No. 23. pp. 4401-4406.
@article{1ed178ac1bbc4da19738c1c571060ca6,
title = "Monoclonal antibody proteomics: Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step",
abstract = "We define mAb proteomics as the global generation of disease specific antibodies that permit mass screening of biomarkers. An integrated, high-throughput, disease-specific mAb-based biomarker discovery platform has been developed. The approach readily provided new biomarker leads with the focus on large-scale discovery and production of mAb-based, disease-specific clinical assay candidates. The outcome of the biomarker discovery process was a highly specific and sensitive assay, applicable for testing of clinical validation paradigms, like response to treatment or correlation with other clinical parameters. In contrast to MS-based or systems biology-based strategies, our process produced prevalidated clinical assays as the outcome of the discovery process. By re-engineering the biomarker discovery paradigm, the encouraging results presented in this paper dearly demonstrate the efficiency of the mAb proteomics approach, and set the grounds for the next steps of studies, namely, the hunt for candidate biomarkers that respond to drug treatment.",
keywords = "Antibody, Biomarker discovery, Proteomics",
author = "Eszter Csanky and Petra Olivova and E. Rajnavolgyi and William Hempel and Nadege Tardieu and Katalin, {Elesne Toth} and Anne Jullien and Carole Malderez-Bloes and Mariana Kuras and Duval, {Manuel X.} and L. Nagy and B. Scholtz and William Hancock and Barry Karger and A. Guttman and Laszlo Takacs",
year = "2007",
month = "12",
doi = "10.1002/elps.200700256",
language = "English",
volume = "28",
pages = "4401--4406",
journal = "Electrophoresis",
issn = "0173-0835",
publisher = "Wiley-VCH Verlag",
number = "23",

}

TY - JOUR

T1 - Monoclonal antibody proteomics

T2 - Discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step

AU - Csanky, Eszter

AU - Olivova, Petra

AU - Rajnavolgyi, E.

AU - Hempel, William

AU - Tardieu, Nadege

AU - Katalin, Elesne Toth

AU - Jullien, Anne

AU - Malderez-Bloes, Carole

AU - Kuras, Mariana

AU - Duval, Manuel X.

AU - Nagy, L.

AU - Scholtz, B.

AU - Hancock, William

AU - Karger, Barry

AU - Guttman, A.

AU - Takacs, Laszlo

PY - 2007/12

Y1 - 2007/12

N2 - We define mAb proteomics as the global generation of disease specific antibodies that permit mass screening of biomarkers. An integrated, high-throughput, disease-specific mAb-based biomarker discovery platform has been developed. The approach readily provided new biomarker leads with the focus on large-scale discovery and production of mAb-based, disease-specific clinical assay candidates. The outcome of the biomarker discovery process was a highly specific and sensitive assay, applicable for testing of clinical validation paradigms, like response to treatment or correlation with other clinical parameters. In contrast to MS-based or systems biology-based strategies, our process produced prevalidated clinical assays as the outcome of the discovery process. By re-engineering the biomarker discovery paradigm, the encouraging results presented in this paper dearly demonstrate the efficiency of the mAb proteomics approach, and set the grounds for the next steps of studies, namely, the hunt for candidate biomarkers that respond to drug treatment.

AB - We define mAb proteomics as the global generation of disease specific antibodies that permit mass screening of biomarkers. An integrated, high-throughput, disease-specific mAb-based biomarker discovery platform has been developed. The approach readily provided new biomarker leads with the focus on large-scale discovery and production of mAb-based, disease-specific clinical assay candidates. The outcome of the biomarker discovery process was a highly specific and sensitive assay, applicable for testing of clinical validation paradigms, like response to treatment or correlation with other clinical parameters. In contrast to MS-based or systems biology-based strategies, our process produced prevalidated clinical assays as the outcome of the discovery process. By re-engineering the biomarker discovery paradigm, the encouraging results presented in this paper dearly demonstrate the efficiency of the mAb proteomics approach, and set the grounds for the next steps of studies, namely, the hunt for candidate biomarkers that respond to drug treatment.

KW - Antibody

KW - Biomarker discovery

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=37149003017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149003017&partnerID=8YFLogxK

U2 - 10.1002/elps.200700256

DO - 10.1002/elps.200700256

M3 - Article

C2 - 18041035

AN - SCOPUS:37149003017

VL - 28

SP - 4401

EP - 4406

JO - Electrophoresis

JF - Electrophoresis

SN - 0173-0835

IS - 23

ER -